Adoptive Cell Therapies (Advanced Cellular Immunotherapy)
When conventional chemotherapy, targeted therapy, and first-line immunotherapies have been exhausted, Adoptive Cell Therapy (ACT) represents the pinnacle of modern bio-cellular oncology. At PCRI, we offer specialized consultations, patient eligibility evaluations, and treatment pathways for advanced cellular immunotherapies designed for refractory, relapsed, and heavily pre-treated metastatic cancers.
Adoptive cell therapy harnesses the patient's own living immune cells, genetically engineering or ex-vivo expanding them into supercharged cancer-fighting cells that seek out and destroy malignant cells with microscopic precision.
Key Adoptive Cell Therapy Modalities
- CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cells): T-lymphocytes harvested from the patient are genetically re-engineered with synthetic receptors targeting cancer-specific antigens (such as CD19, BCMA). Clinically validated with unprecedented remissions in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL), and Multiple Myeloma.
- Natural Killer (NK) Cell Therapy: Infusion of allogeneic or autologous activated NK cells that target tumors independently of antigen presentation, providing a potent anti-tumor effect without inducing graft-versus-host disease (GVHD).
- Tumor-Infiltrating Lymphocytes (TILs): Extraction, vigorous laboratory expansion, and re-infusion of tumor-specific immune cells harvested from surgical biopsy specimens, particularly effective in refractory metastatic melanoma and solid tumors.
- Dendritic Cell Vaccines: Antigen-presenting cell therapies engineered to train the host immune system to mount a durable, systemic T-cell response against cancer antigens.
Specialized Clinical Management at PCRI
Administering cellular therapies requires expert oncological vigilance. PCRI's clinical team is specifically trained in the prevention, early recognition, and multi-disciplinary management of unique cellular therapy side effects:
- Cytokine Release Syndrome (CRS) Protocol: Rapid grading and prompt intervention using IL-6 receptor antagonists (Tocilizumab) and supportive care.
- Immune Effector Cell-Associated Neurotoxicity (ICANS): Neurological monitoring protocols ensuring maximum patient safety.
- Comprehensive Pre-Infusion Lymphodepletion: Optimizing the host bone marrow microenvironment to maximize adoptive cell expansion and therapeutic persistence.
Gallery
